CereVasc eShunt System’s STRIDE Trial Enrolls First Patient

January 14, 2025—CereVasc, Inc. announced that the first patient was enrolled in the STRIDE clinical trial of the company’s eShunt system to treat patients with normal pressure hydrocephalus (NPH).

According to the company, the multicenter, randomized controlled STRIDE trial will assess the safety and efficacy of the eShunt system compared with the standard-of-care ventriculoperitoneal (VP) shunt in the treatment of elderly patients diagnosed with NPH. The trial will be conducted at sites in the United States and around the world. The company’s trial website is https://nphstridestudy.com/.

The results of the STRIDE trial will serve as the basis for the company’s future premarket approval submission to the FDA. The eShunt system is currently an investigational device and not available for sale within or outside the United States, advised the company. advised CereVasc.

“The groundswell of excitement amongst patients and in the medical community is a true testament to the need for innovation in treating these patients,” commented Charles Matouk, MD, in the company’s press release. Dr. Matouk, who is Professor of Neurosurgery at Yale School of Medicine in New Haven, Connecticut, serves as a lead investigator of the STRIDE study.

Dr. Matouk continued, “Fear of conventional open neurosurgery is common, and patients are enthusiastic about the prospect of receiving safe and effective treatment for NPH in a minimally invasive way. The eShunt system could dramatically improve quality of life for older people living with this disease.”

Pedro Lylyk, MD, a colead investigator of the trial and a neurosurgeon at Clinica la Sagrada Familia in Buenos Aires, Argentina, added, “The eShunt system is helping to usher in a new era in neurosurgery for shorter, less invasive procedures that foster patient eligibility and willingness to undergo treatment. With its potential to improve safety and reduce recovery time in those being treated for NPH, CereVasc’s technology could change the standard of care for this common neurological disease.”